Inclusion Criteria:  The patients voluntarily participated in the study and signed the informed consent 18-75 female Cervical squamous cell carcinoma / adenocarcinoma / adenosquamous cell carcinoma According to International Federation of Gynecology and Obstetrics(FIGO) 2009 stage, stage ⅠB2 - ⅣA with positive pelvic lymph nodes and negative common iliac and paraaortic lymph nodes diagnosed by PET-CT Cisplatin chemotherapy is acceptable Eastern Cooperative Oncology Group(ECOG) score 0-1 The expected survival was more than 6 months Women of childbearing age must have a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they are willing to use appropriate contraceptive methods during the test According to the judgment of the researcher, those who can comply with the trial protocol  Exclusion Criteria:  Uncontrolled severe infection Combined with other malignant tumor patients who need treatment and / or new diagnosis within 5 years The patient has received anti-tumor treatment Liver cirrhosis, decompensated liver disease, chronic renal insufficiency and renal failure History of immunodeficiency, including HIV positive or other acquired congenital immunodeficiency disease Myocardial infarction, severe arrhythmia and grade 2 or more congestive heart failure (NYHA classification) Patients with previous pelvic artery embolization Previous radiotherapy for pelvic malignant tumor There was a history of severe allergic reaction to platinum containing chemotherapy drugs Complications, need to be taken during the treatment of liver and kidney function damage drugs, such as tuberculosis The patients who could not understand the content of the experiment and could not cooperate and refused to sign the informed consent Patients with accompanying diseases or other special circumstances that seriously endanger the safety of patients or affect the completion of the study